Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 18/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952967 | 0.90 | EPHX2 (0.64) | EPHX2CYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2922679 | 0.88 | ROCK2 (0.46) | EPHX2PPARGROCK2ROCK1 | |
| SCHEMBL2908998 | 0.86 | EPHX2 (0.64) | EPHX2CYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3470338 | 0.85 | EPHX2 (0.59) | EPHX2CYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3469886 | 0.83 | HDAC8 (0.43) | EPHX2ROCK2ROCK1 | |
| SCHEMBL3036291 | 0.82 | EPHX2 (0.62) | EPHX2CYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3470922 | 0.80 | EPHX2 (0.49) | EPHX2CYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3474823 | 0.80 | EPHX2 (0.79) | EPHX2CYP2C9 | |
| SCHEMBL2904563 | 0.79 | EPHX2 (0.62) | EPHX2CYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2954996 | 0.78 | EPHX2 (0.49) | EPHX2CYP2C9PPARGROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | claimed |
| EP-2224928-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-09-08 | — | — | EP | claimed |
| WO-2009073772-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | claimed |
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | disclosed |
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | disclosed |
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | disclosed |
| EP-2224928-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009073772-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073772-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | EPHX1, REN, NCEH1 | EPHX2 9/4885CYP2C9 217/4885CYP3A4 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.